NASDAQ · Biological Products, (No Diagnostic Substances)
Last close $110.40 · 2026-09-30
ABOUT
ExchangeNASDAQ
SectorHealthcare
IndustryBiological Products, (No Diagnostic Substances)
Market cap$12.53B
RECENT INSIDER TRADES
2026-10-08 · Torley Helen (PRESIDENT AND CEO) · SELL
2026-10-08 · Torley Helen (PRESIDENT AND CEO) · OTHER
INSTITUTIONAL OWNERSHIP
Institutional holders732
Shares held157,595,238
Value$11.14B
Percent of shares outstanding138.85%
As of quarter end2026-06-30
RECENT NEWS
HALO: Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
HALO: Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology
Halozyme appoints Jim Daly to Board of Directors
Halozyme Therapeutics announces $1.5B offering
Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost?